Novavax (NVAX) Projected to Post Quarterly Earnings on Friday

Novavax (NASDAQ:NVAX) is anticipated to announce its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of $0.19 per share and revenue of $204.08 million for the quarter.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.24. The business had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the previous year, the firm earned ($1.44) EPS. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Trading Down 3.2 %

NVAX stock opened at $6.07 on Wednesday. The company’s 50 day moving average is $6.97 and its two-hundred day moving average is $8.10. Novavax has a twelve month low of $4.43 and a twelve month high of $23.86. The stock has a market cap of $976.32 million, a P/E ratio of -2.69, a PEG ratio of 2.85 and a beta of 3.21.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. BTIG Research began coverage on Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 target price for the company. TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.